molecular insight makes debut new york molecular insight pharmaceuticals inc rose slightly on its first day of trading as a public company closing the busiest week for new stocks so far this year with six deals the initial public offering of stock in the cambridge mass company closed at &# a share on the nasdaq stock market nine cents higher than its ipo price of &# a share the company sold five million shares at the low end of its expected &# to &# price range set by lead underwriters rbc capital markets and jefferies &amp co 
